A Phase 3 interventional study of Sintilimab and Cisplatin in Esophageal Squamous Cell Carcinoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 48 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-24.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma — 9 open to participants now, 9 under way, 4 of them phase 3. sintilimab · Esophageal Squamous Cell Carcinoma.
Among the 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma, this one has the largest enrollment, is the only one that started in 2018, is one of 5 in phase 3, and was the 2nd registered.
678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →9 of the 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma are open now, in 1 country. Recruiting first, the newest first:
Shanghai Chest Hospital · Sites in China
Ages 20–75
Fujian Cancer Hospital · Sites in China
Ages 18–75
Zhejiang Cancer Hospital · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–70
Henan Cancer Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 746 is above the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 52 across the 21 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Innovent Biologics, Inc. has 2 studies filed under Esophageal Squamous Cell Carcinoma — fewer than ten, so there is no comparison to draw.
1 of the studies testing sintilimab in Esophageal Squamous Cell Carcinoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07016737Phase 3Ye jinjunImmunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma.
After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilimab in combination with chemotherapy in subjects representing the western population with advanced esophageal squamous cell carcinoma
Key Inclusion Criteria:
Key exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sintilimab in combination with investigator's choice of chemotherapy TP regimen: Cisplatin + paclitaxel or CP regimen: Cisplatin + fluorourcil
Biological: Sintilimab · Drug: Cisplatin · Drug: Paclitaxel · Drug: Fluorouracil
Placebo in combination with investigator's choice of chemotherapy TP regimen: Cisplatin + paclitaxel or CP regimen: Cisplatin + fluorourcil
Drug: Cisplatin · Drug: Paclitaxel · Drug: Fluorouracil · Drug: Placebo
Sintilimab in combination with investigator's choice of chemotherapy TP regimen: Cisplatin + paclitaxel or CP regimen: Cisplatin + fluorourcil
Biological: Sintilimab · Drug: Cisplatin · Drug: Paclitaxel · Drug: Fluorouracil
For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
75mg/m\^2 IV Q3W day 1
87.5 mg/m\^2 IV Q3W day 1, day 8 for first cycle and 175mg/m\^2 IV Q3W day 1 after first cycle
800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W
For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
OS in overall population
To compare the overall survival of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
Time frame: From date of randomization until the date of death from any cause, assessed up to 40 months.
OS in PD-L1 positive population
To compare the OS of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with PD-L1 positive, unresectable, locally advanced, recurrent or metastatic ESCC
Time frame: From date of randomization until the date of death from any cause, assessed up to 40 months.
ORR in overall population
To compare the objective response rate between the two treatment arms in ITT population
Time frame: From date of randomization up to 28 months.
PFS in overall populationsubjects in ITT population
To compare the progression-free survival between the two treatment arms in ITT population
Time frame: From date of randomization up to 28 months
DCR in overall population
To compare the disease control rate between the two treatment arms in ITT population
Time frame: From date of randomization up to 28 months
DoR in overall population
To compare the duration of response between the two treatment arms in ITT population
Time frame: From date of randomization up to 28 months
ORR - PD-L1 positive
To compare the objective response rate between the two treatment arms in PD-L1 positive subjects in ITT population
Time frame: From date of randomization up to 28 months
DCR - PD-L1 positive
To compare the disease control rate between the two treatment arms in PD-L1 positive subjects in ITT population
Time frame: From date of randomization up to 28 months
DoR - PD-L1 positive
To compare the duration of response between the two treatment arms in PD-L1 positive subjects in ITT population
Time frame: From date of randomization up to 28 months
PFS - PD-L1 positive
To compare the progression-free survival between the two treatment arms in PD-L1 positive subjects in ITT population
Time frame: From date of randomization up to 28 months
Plan to share: No
Ran from Dec 2018 to primary completion in Sep 2021, 32 months.
Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's 32 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sintilimab
Esophageal Squamous Cell Carcinoma →
Innovent Biologics (Suzhou) Co. Ltd. →